| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
From the Departments of Neurochemistry (Drs. Giovannoni and E. Thompson), Clinical Neurology (Drs. Giovanni, A. Thompson, and Miller), and Neurorehabilitation (Dr. A. Thompson), Institute of Neurology, London, United Kingdom.
Address correspondence and reprint requests to Dr. G. Giovannoni, Institute of Neurology, Queen Square, London WC1N 3BG, UK; e-mail: G.Giovannoni{at}ion.ucl.ac.uk
Background:— The pathogenesis of fatigue in patients with MS is poorly understood.
Objective:— To test the hypothesis that fatigue in MS is related to inflammatory disease activity as measured by systemic markers of inflammation.
Methods:— Fatigue as assessed by the Fatigue Questionnaire Scale (FQS) and Krupp’s Fatigue Severity Scale (KFSS) was correlated with several inflammatory markers in 38 patients with MS (16 relapsing–remitting [RR; 7 of whom had benign MS), 9 secondary progressive [SP], 13 primary progressive [PP]). The markers included daily urinary neopterin excretion, a marker of interferon-
-activated macrophage activity, and serum C-reactive protein (CRP) and soluble intercellular adhesion molecule-1 (sICAM-1) levels. Urinary neopterin excretion was measured daily for 2 weeks.
Results:— No correlation was found between urinary neopterin excretion, CRP, or sICAM-1 and the fatigue scores. However, patients with a raised serum CRP level had higher KFSS, but not FQS, scores than patients with normal CRP levels (KFSS, 50 ± 8 vs 41 ± 14, p = 0.05; FQS, 13 ± 4 vs 11 ± 5, p = NS). When assessed using the FQS, patients with RR and SP MS were more fatigued than patients with PP MS (RR = 12.5 [4 to 23] vs SP = 13 [8 to 18] vs PP = 9 [7 to 14], p = 0.02). The patients with benign MS were as fatigued as patients with nonbenign disease.
Conclusion:— The pathogenesis of fatigue in MS is complex and does not appear to be directly related to systemic markers of inflammatory disease activity. Interestingly, patients with PP MS were less fatigued than patients with RR disease.
This article has been cited by other articles:
|
|
 |
|
  R F Brown, C C Tennant, M Sharrock, S Hodgkinson, S M Dunn, and J D Pollard Relationship between stress and relapse in multiple sclerosis: part II. Direct and indirect relationships Multiple Sclerosis, August 1, 2006; 12(4): 465 - 475. [Abstract] [PDF]
|
|
|
|
|
|
N. Tellez, M. Comabella, E v. Julia, J. Rio, M a. Tintore, L. Brieva, C. Nos, and X. Montalban Fatigue in progressive multiple sclerosis is associated with low levels of dehydroepiandrosterone Multiple Sclerosis, August 1, 2006; 12(4): 487 - 494. [Abstract] [PDF]
|
|
|
|
 |
|
 G Giovannoni Multiple sclerosis related fatigue J. Neurol. Neurosurg. Psychiatry, January 1, 2006; 77(1): 2 - 3. [Full Text] [PDF]
|
|
|
|
 |
|
 B. Stankoff, E. Waubant, C. Confavreux, G. Edan, M. Debouverie, L. Rumbach, T. Moreau, J. Pelletier, C. Lubetzki, M. Clanet, et al. Modafinil for fatigue in MS: A randomized placebo-controlled double-blind study Neurology, April 12, 2005; 64(7): 1139 - 1143. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N Tellez, J Rio, M Tintore, C Nos, I Galan, and X Montalban Does the Modified Fatigue Impact Scale offer a more comprehensive assessment of fatigue in MS? Multiple Sclerosis, April 1, 2005; 11(2): 198 - 202. [Abstract] [PDF]
|
|
|
|
 |
|
 M. Gottschalk, T. Kumpfel, P. Flachenecker, M. Uhr, C. Trenkwalder, F. Holsboer, and F. Weber Fatigue and Regulation of the Hypothalamo-Pituitary-Adrenal Axis in Multiple Sclerosis Arch Neurol, February 1, 2005; 62(2): 277 - 280. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Flachenecker, I. Bihler, F Weber, M Gottschalk, K. V Toyka, and P. Rieckmann Cytokine mRNA expression in patients with multiple sclerosis and fatigue Multiple Sclerosis, April 1, 2004; 10(2): 165 - 169. [Abstract] [PDF]
|
|
|
|
|
|
M. K. Racke, K. Hawker, and E. M. Frohman Fatigue in Multiple Sclerosis: Is the Picture Getting Simpler or More Complex? Arch Neurol, February 1, 2004; 61(2): 176 - 177. [Full Text] [PDF]
|
|
|
|
|
|
J. Iriarte and G. Giovannoni Fatigue is not associated with raised inflammatory markers in multiple sclerosis Neurology, April 9, 2002; 58(7): 1134 - 1135. [Full Text] [PDF]
|
|
|
|
|
|
E Willoughby Modafinil for fatigue in multiple sclerosis J. Neurol. Neurosurg. Psychiatry, February 1, 2002; 72(2): 150 - 150. [Abstract] [Full Text] [PDF]
|
|
Read all Correspondence
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
